Abstract:5452 Although chemotherapy used as a primary therapy for many cancers is to cause massive cell death, there are some residual cancer cells that remain alive. Gene therapy can target cancer cells with specific genetic defect(s) which provides an attractive regimen to eradicate those cells. Transitional cell carcinoma (TCC) of bladder is considered as an ideal model for evaluating the combination of chemotherapy and adenovirus-based gene therapy. However, it is known that coxsackie and adenovirus receptor (CAR), first identified as a high affinity adenovirus receptor, is often down regulated in human TCC cells. Therefore, the objective of this study is to screen any chemotherapeutic agent that can not only kill TCC cells but also upregulate CAR expression in cancer cells. We have used two TCC cell lines (i.e., T24 and TCC-SUP) expressing low endogenous levels of CAR protein. Several techniques and assays employed in this study were: (1) real-time RT-PCR for determining the steady-state levels of CAR mRNA; (2) western blot analysis for determining the CAR protein expression; (3) β-gal assay for measuring the transgene expression in target cells infected with β-gal adenovirus; (4) crystal violet assay for determining the effect of chemotherapeutic agents or virus on TCC; (5) in vitro histone deacetylase (HDAC) activity assay for determining the total HDAC activity in the nuclear extract of cells. One known mechanism of down-regulation of CAR gene in TCC cells is due to the decreased histone acetylation associated with the promoter region of this gene. In this study, we have screened a chemical library and discovered an anti-allergic agent, Tranilast (N-3, 4-dimethoxycinnamoyl anthranilic acid) as a potential candidate of CAR gene inducer. In general, Tranilast alone is a weak CAR gene inducer. By combining Tranilast with a low dose of FK228 (an HDAC inhibitor), we observed a synergistic effect on CAR mRNA expression in both T24 and TCC-SUP cells. Based on the structure of Tranilast, we further identified an analog (i.e., 2, 3-dimethoxycinnamoyl azide [DMCA]), when combined with FK228, has a more potent effect than the combination of Tranilast and FK228 on both CAR gene expression and virus uptake in TCC cells, which is consistent with the increased suppression of HDAC activity in treated cells. To determine the therapeutic effect on TCC cells, we observed that either Tranilast or DMCA alone did not cause any obvious cytotoxic effect. However, in combination with a low dosage of FK228, DMCA can significantly potentiate the growth inhibitory effect of FK228 on both T24 and TCC-SUP cells. In summary, our data indicate that DMCA in combination with FK228 can be used as a primary chemotherapeutic regimen for TCC and, with the elevation of CAR expression, a subsequent adenovirus gene therapy can then be used as an adjuvant therapy for any remaining cancer cells.

Enhancing The Inductive Activity Of Depsipeptide (Fk228) On Adenovirus Receptor And Its Therapeutic Efficacy On The Treatment Of Human Bladder Cancer By Tranilast And Its Analogue.

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

Adenovirus-mediated Tissue-Specific Cytosine Deaminase Gene Therapy for Human Hepatocellular Carcinoma with Different AFP Expression Levels.

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Arg-Gly-Asp (Rgd)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells in Vitro and in Mice

Combined Use of Chemotherapeutics and Oncolytic Adenovirus in Treatment of AFP-expressing Hepatocellular Carcinoma

Full Remission of CAR-Deficient Tumors by DOTAP-Folate Liposome Encapsulation of Adenovirus

Adenovirus-mediated Inhibitor Kappab Gene Transfer Improves the Chemosensitivity to Anticancer Drugs in Human Lung Cancer in Vitro and in Vivo.

A Novel Bladder Cancer - Specific Oncolytic Adenovirus by CD46 and Its Effect Combined with Cisplatin Against Cancer Cells of CAR Negative Expression

Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer

Proteasome Inhibitor Mg-132 Modifies Coxsackie and Adenovirus Receptor Expression in Colon Cancer Cell Line Lovo

Efficacy of adenovirus-mediated CD gene combined with prodrugs and α-IFN for treatment of human renal clear carcinoma

Antitumor Effects of Bladder Cancer-Specific Adenovirus Carrying E1A-androgen Receptor in Bladder Cancer

Genetically Modified Adenoviral Vector with the Protein Transduction Domain of Tat Improves Gene Transfer to CAR-deficient Cells

Rejection of Adenovirus Infection is Independent of Coxsackie and Adenovirus Receptor Expression in Cisplatin-Resistant Human Lung Cancer Cells

The Use of Histone Deacetylase Inhibitor Fk228 and Dna Hypomethylation Agent 5-Azacytidine in Human Bladder Cancer Therapy

[Construction of CYP2E1 Recombinant Adenovirus Vector and Its Anti-Tumor Effects].

Combination of Adenovirus and Cross-Linked Low Molecular Weight PEI Improves Efficiency of Gene Transduction.

Fiber-modified Adenovirus-Mediated Suicide Gene Therapy Can Efficiently Eliminate Bladder Cancer Cells in Vitro and in Vivo

Synergistic Effect of Bladder Cancer-Specific Oncolytic Adenovirus in Combination with Chemotherapy.

A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma